AU2006210994A1 - Assays for agents with selective cytotoxicty to HDAC resistant cell lines - Google Patents
Assays for agents with selective cytotoxicty to HDAC resistant cell lines Download PDFInfo
- Publication number
- AU2006210994A1 AU2006210994A1 AU2006210994A AU2006210994A AU2006210994A1 AU 2006210994 A1 AU2006210994 A1 AU 2006210994A1 AU 2006210994 A AU2006210994 A AU 2006210994A AU 2006210994 A AU2006210994 A AU 2006210994A AU 2006210994 A1 AU2006210994 A1 AU 2006210994A1
- Authority
- AU
- Australia
- Prior art keywords
- hdaci
- resistant
- test agent
- inhibitor
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65014105P | 2005-02-07 | 2005-02-07 | |
US60/650,141 | 2005-02-07 | ||
PCT/GB2006/000425 WO2006082448A1 (en) | 2005-02-07 | 2006-02-06 | Assays for agents with selective cytotoxicty to hdac resistant cell lines |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2006210994A1 true AU2006210994A1 (en) | 2006-08-10 |
Family
ID=35978552
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2006210994A Abandoned AU2006210994A1 (en) | 2005-02-07 | 2006-02-06 | Assays for agents with selective cytotoxicty to HDAC resistant cell lines |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1856522A1 (de) |
JP (1) | JP2008529487A (de) |
AU (1) | AU2006210994A1 (de) |
CA (1) | CA2596405A1 (de) |
WO (1) | WO2006082448A1 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2627500T3 (es) | 2012-07-13 | 2017-07-28 | Turun Yliopisto | Terapia de combinación |
JP6294614B2 (ja) * | 2013-05-08 | 2018-03-14 | 有限会社マイテック | 癌関連物質の定量方法 |
CN107954893A (zh) * | 2017-11-28 | 2018-04-24 | 兰州纬寰生物科技有限公司 | 邻氨基苯甲酰胺衍生物及制备方法和用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9325395D0 (en) * | 1993-12-11 | 1994-02-16 | Ciba Geigy Ag | Compositions |
US20010053773A1 (en) * | 1998-12-22 | 2001-12-20 | The Procter & Gamble Company | Method for inhibiting the growth of cancers |
US20080233562A1 (en) * | 2003-02-19 | 2008-09-25 | Astellas Pharma Inc. | Method of Estimating Antitumor Effect of Histone Deacetylase Inhibitor |
-
2006
- 2006-02-06 WO PCT/GB2006/000425 patent/WO2006082448A1/en active Application Filing
- 2006-02-06 EP EP06709669A patent/EP1856522A1/de not_active Withdrawn
- 2006-02-06 AU AU2006210994A patent/AU2006210994A1/en not_active Abandoned
- 2006-02-06 CA CA002596405A patent/CA2596405A1/en not_active Abandoned
- 2006-02-06 JP JP2007553709A patent/JP2008529487A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2596405A1 (en) | 2006-08-10 |
WO2006082448A1 (en) | 2006-08-10 |
EP1856522A1 (de) | 2007-11-21 |
JP2008529487A (ja) | 2008-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6511990B1 (en) | Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | |
US20220160721A1 (en) | Methods of treating cancer | |
EP1427403B1 (de) | Valproinsäure zur Behandlung von Brustkrebs, Dickdarmkrebs, Kopf-Hals-Krebs, kleinzelligem Lungenkarzinom und Blutzellenkrebs in Kombination mit Bestrahlung | |
US7550490B2 (en) | Benzamide derivatives as histone deacetylase inhibitors with potent differentiation and anti-proliferation activity | |
CA2552279C (en) | Zn2+-chelating motif-tethered short -chain fatty acids as a novel class of histone deacetylase inhibitors | |
US8236985B2 (en) | Compounds and uses thereof | |
CN103764604B (zh) | 茋类似物和治疗癌症的方法 | |
JP4644829B2 (ja) | ヒストン脱アセチル化酵素阻害剤としての新規な化合物 | |
US10758513B2 (en) | Modulators of mitochondrial protein import | |
JP2011516473A (ja) | 医薬組成物 | |
AU2006210994A1 (en) | Assays for agents with selective cytotoxicty to HDAC resistant cell lines | |
WO2008068170A1 (en) | Hdac inhibitors | |
JP2024023269A (ja) | 抗腫瘍剤及び配合剤 | |
US7351861B2 (en) | Method and probe for identifying bacterial virulence modifying agents, agents thus identified, and their use | |
Kortenhorst et al. | Acetylation and histone deacetylase inhibitors in cancer | |
US20040198727A1 (en) | Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment the anti-cancer activity of DNA damaging treatments | |
CN117756742A (zh) | 苯并噻唑类化合物或其盐、其制备方法及应用 | |
JP4150792B2 (ja) | 血液脳関門におけるキノリン酸の輸送を評価する方法 | |
AU2002231190A1 (en) | Methods for inducing apoptosis and inhibiting proliferation in cancer cells | |
WO2002051406A9 (en) | Methods for inducing apoptosis and inhibiting proliferation in cancer cells | |
WO2020257753A1 (en) | Phosphatidylserine decarboxylase inhibitors | |
AU2007207869B2 (en) | Valproic acid and derivatives for the combinatorial therapeutic treatment of human cancers and for the treatment of tumor metastasis and minimal residual disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |